- 多發性硬化症 (MS) 是一種影響中樞神經系統的慢性自體免疫疾病，會導致殘疾。多發性硬化症治療的需求很大程度上受到該疾病盛行率上升和治療方案進步的推動。例如，由於人們認識的提高、診斷技術的進步和醫療保健系統的改善，美國、加拿大和瑞典、挪威等歐洲國家的多發性硬化症病例數量一直在穩步上升
- 多發性硬化症 (MS) 療法的需求主要源於對疾病修飾療法 (DMT) 的需求，這種療法旨在降低復發的頻率和嚴重程度、減緩疾病進展並控制症狀
- 例如，DMT 的進步是 Gilenya（芬戈莫德）和 Tecfidera（富馬酸二甲酯）等口服藥物的批准，它們為注射治療提供了便捷的替代方案，並在減少 MS 復發方面顯示出良好的效果。
- 在全球範圍內，疾病改良療法 (DMT) 仍然是 MS 治療市場的基石，其次是針對症狀管理的療法。口服藥物和單株抗體等生物療法的發展進一步改善了患者的治療選擇
Frequently Asked Questions
The U.S. is expected to dominate the multiple sclerosis market due to its large patient population, advanced healthcare infrastructure, and high adoption of innovative treatments.
North America dominates the multiple sclerosis (MS) market, driven by advanced healthcare infrastructure, high adoption of innovative treatment options, and a strong presence of key pharmaceutical companies.
China is expected to witness the highest CAGR in the multiple sclerosis market, driven by an increasing prevalence of MS, improving healthcare infrastructure, and rising awareness about treatment options.
Factors driving the growth of the multiple sclerosis market include the rising prevalence of MS globally, advancements in disease-modifying therapies, and increased awareness and early diagnosis.
Major challenges in the multiple sclerosis market include the high cost of advanced therapies, which limits accessibility for many patients, and the variability in treatment response among individuals.
